FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

10 letters match. Newest first.

  1. HealthPartners Neuroscience Center Research and Innovation

    FDA warned HealthPartners Neuroscience Center that its animal studies of an investigational drug violated good laboratory practice rules.

    Medium
  2. Pamela K. Den Besten, DDS, MS

    FDA warned sponsor-investigator Pamela K. Den Besten for running a pediatric dental gel study without an IND, enrolling 43 subjects.

    High risk
  3. Amy Lightner, MD

    FDA warns sponsor-investigator Amy Lightner, MD over clinical trial violations, including dosing before eligibility tests and unreported serious adverse events.

    High risk
  4. Angela D. Ritter, M.D.

    FDA warns Dr. Angela Ritter over unauthorized dosing of an investigational drug and missing ethics-board review.

    High risk
  5. Bret R. Rutherford, M.D.

    FDA warned Dr. Bret R. Rutherford for enrolling ineligible patients in two drug studies by skipping required antidepressant washout.

    High risk
  6. Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

    FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.

    High risk
  7. "David M. Lubeck, M.D./Arbor Centers for EyeCare

    FDA warned Dr. David Lubeck for running a combination-drug study without an IND and enrolling five subjects.

    High risk
  8. Daniel Fred Goodman, M.D./Goodman Eye Center

    FDA warns Dr. Daniel Fred Goodman/Goodman Eye Center over clinical drug study without required FDA application and missing consent/assent.

    High risk
  9. Lauren R. Klein, MD, M.S.

    FDA cited Dr. Lauren R. Klein for running two emergency department drug studies without required investigational new drug applications.

    High risk
  10. Jon B. Cole, MD

    FDA warns Dr. Jon B. Cole he ran two pre-hospital drug studies without required INDs, adding risks for pregnant women, children, and intoxicated patients.

    High risk